Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. US Stem Cell's Revenue for the
three
months ended in Dec. 2022 was $0.02 Mil. US Stem Cell's Total Assets for the quarter that ended in Dec. 2022 was $0.12 Mil. Therefore, US Stem Cell's Asset Turnover for the quarter that ended in Dec. 2022 was 0.17.
Asset Turnover is linked to ROE % through Du Pont Formula. US Stem Cell's annualizedROE % for the quarter that ended in Dec. 2022 was 15.67%. It is also linked to ROA % through Du Pont Formula. US Stem Cell's annualizedROA % for the quarter that ended in Dec. 2022 was -1,890.00%.
US Stem Cell Asset Turnover Historical Data
The historical data trend for US Stem Cell's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's Asset Turnover
For the Biotechnology subindustry, US Stem Cell's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Asset Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Asset Turnover distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Asset Turnover falls into.
US Stem Cell Asset Turnover Calculation
Asset Turnover measures how quickly a company turns over its asset through sales.
US Stem Cell's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
US Stem Cell (OTCPK:USRM) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
US Stem Cell's annulizedROE % for the quarter that ended in Dec. 2022 is
Note:
The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
US Stem Cell's annulizedROA % for the quarter that ended in Dec. 2022 is
Note:
The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
US Stem Cell Asset Turnover Related Terms
Thank you for viewing the detailed overview of US Stem Cell's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 